Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilaprisan versus standard of care for uterine fibroids
2016-004822-41Phase 3Completed
- Sponsor
- Bayer
- Start
- Apr 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Fibromyoma (LM) comparing Vilaprisan with Nonhormonal standard of care (2 arms). Primary endpoint: Percentage of change in bone mineral density of lumbar spine. Started Apr 2017; status: completed.
02
Drugs
vilaprisan
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on 2016-004822-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004822-41.